Expert discusses emerging agents and the future of follicular lymphoma
Monday, January 18, 2016
John Leonard, M.D.
Indolent lymphoma accounts for approximately 30 percent of patients with non-Hodgkin lymphoma (NHL)., medical oncology, at Weill Cornell Medicine and NewYorkPresbyterian Hospital.
“When patients relapse after initial therapy, the key factors in choosing a treatment include the time from first therapy, the time to reoccurrence, how sick they are, their age, and what they need in terms of symptom relief at that time,” says Leonard.
Standard treatment options include single-agent rituximab (Rituxan) and chemotherapy with rituximab. However, a number of new approaches for indolent lymphoma and more are on the horizon, Leonard says.
In an interview with OncLive, Leonard discusses the potential for lenalidomide (Revlimid), idelalisib (Zydelig), and ibrutinib (Imbruvica) in follicular lymphoma, possible combination therapies, and challenges that remain in the treatment of the disease.
In an interview with OncLive, Leonard discusses the potential for lenalidomide (Revlimid), idelalisib (Zydelig), and ibrutinib (Imbruvica) in follicular lymphoma, possible combination therapies, and challenges that remain in the treatment of the disease.
Read the full interview here.
